55 related articles for article (PubMed ID: 12218419)
21. Neophobia and cortical and subcortical binding of the dopamine D2 receptor antagonist [3H]-raclopride.
Siemiatkowski M; Maciejak P; Wisłowska A; Zienowicz M; Sienkiewicz-Jarosz H; Szyndler J; Członkowska AI; Bidziński A; Gryczyńska A; Płaźnik A
Life Sci; 2004 Dec; 76(7):753-61. PubMed ID: 15581907
[TBL] [Abstract][Full Text] [Related]
22. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E
Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182
[TBL] [Abstract][Full Text] [Related]
23. Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm.
Bailey A; Metaxas A; Yoo JH; McGee T; Kitchen I
Eur J Neurosci; 2008 Aug; 28(4):759-70. PubMed ID: 18671743
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
25. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.
Campos-Romo A; Ojeda-Flores R; Moreno-Briseño P; Fernandez-Ruiz J
J Neurosci Methods; 2009 Mar; 177(2):361-8. PubMed ID: 19022292
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives for dopamine D4 receptor imaging.
Oh SJ; Lee KC; Lee SY; Ryu EK; Saji H; Choe YS; Chi DY; Kim SE; Lee J; Kim BT
Bioorg Med Chem; 2004 Nov; 12(21):5505-13. PubMed ID: 15465327
[TBL] [Abstract][Full Text] [Related]
27. Concept of reaction volume in the in vivo ligand-receptor model.
Delforge J; Syrota A; Bendriem B
J Nucl Med; 1996 Jan; 37(1):118-25. PubMed ID: 8543980
[TBL] [Abstract][Full Text] [Related]
28. Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis.
Swillens S
Mol Pharmacol; 1995 Jun; 47(6):1197-203. PubMed ID: 7603460
[TBL] [Abstract][Full Text] [Related]
29. Theoretical analysis of ligand-binder complex formation: partial equilibrium and incubation time.
McPherson RA; Zettner A
Ann Clin Lab Sci; 1978; 8(6):483-8. PubMed ID: 736513
[TBL] [Abstract][Full Text] [Related]
30. Transient equilibrium determination of dopamine D
Phan JA; Wong DF; Chang NHS; Kumakura Y; Bauer WR; Gjedde A
Front Nucl Med; 2022; 2():. PubMed ID: 36926525
[TBL] [Abstract][Full Text] [Related]
31. [Determining the parameters for receptor-ligand interaction by serial dilution method for the case when the ligand and receptor are in a pre-existing mixture].
Bobrovnik SA
Ukr Biokhim Zh (1999); 2005; 77(4):138-45. PubMed ID: 16568617
[TBL] [Abstract][Full Text] [Related]
32. [Effect of ligand concentration on the precision of determining the parameters of ligand-receptor interaction by serial dilution methods].
Bobrovnik SA
Ukr Biokhim Zh (1999); 2004; 76(3):142-8. PubMed ID: 19621754
[TBL] [Abstract][Full Text] [Related]
33. Four decades of mapping and quantifying neuroreceptors at work
Gjedde A; Wong DF
Front Neurosci; 2022; 16():943512. PubMed ID: 36161158
[TBL] [Abstract][Full Text] [Related]
34. Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation.
Krohn KA; Vera DR
Nucl Med Biol; 2021 Jan; 92():5-23. PubMed ID: 32331709
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Rodent Brain Receptor Imaging.
Herfert K; Mannheim JG; Kuebler L; Marciano S; Amend M; Parl C; Napieczynska H; Maier FM; Vega SC; Pichler BJ
Mol Imaging Biol; 2020 Apr; 22(2):223-244. PubMed ID: 31168682
[TBL] [Abstract][Full Text] [Related]
36. Measurement of Bmax and Kd with the glycine transporter 1 radiotracer ¹⁸F-MK6577 using a novel multi-infusion paradigm.
Xia Y; Zheng MQ; Holden D; Lin SF; Kapinos M; Ropchan J; Gallezot JD; Huang Y; Carson RE
J Cereb Blood Flow Metab; 2015 Dec; 35(12):2001-9. PubMed ID: 26198176
[TBL] [Abstract][Full Text] [Related]
37. Measuring α4β2* nicotinic acetylcholine receptor density in vivo with [(18)F]nifene PET in the nonhuman primate.
Hillmer AT; Wooten DW; Slesarev MS; Ahlers EO; Barnhart TE; Schneider ML; Mukherjee J; Christian BT
J Cereb Blood Flow Metab; 2013 Nov; 33(11):1806-14. PubMed ID: 23942367
[TBL] [Abstract][Full Text] [Related]
38. Determination of in vivo Bmax and Kd for 11C-GR103545, an agonist PET tracer for κ-opioid receptors: a study in nonhuman primates.
Tomasi G; Nabulsi N; Zheng MQ; Weinzimmer D; Ropchan J; Blumberg L; Brown-Proctor C; Ding YS; Carson RE; Huang Y
J Nucl Med; 2013 Apr; 54(4):600-8. PubMed ID: 23424192
[TBL] [Abstract][Full Text] [Related]
39. Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.
Salinas C; Weinzimmer D; Searle G; Labaree D; Ropchan J; Huang Y; Rabiner EA; Carson RE; Gunn RN
J Cereb Blood Flow Metab; 2013 May; 33(5):700-7. PubMed ID: 23385202
[TBL] [Abstract][Full Text] [Related]
40. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol.
Vandehey NT; Moirano JM; Converse AK; Holden JE; Mukherjee J; Murali D; Nickles RJ; Davidson RJ; Schneider ML; Christian BT
J Cereb Blood Flow Metab; 2010 May; 30(5):994-1007. PubMed ID: 20040928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
